Sarah Tabrizi, UCL Institute of Neurology, London, UK
Sarah Tabrizi is a professor of clinical neurology and is the director of the University College of London (UCL) Huntington’s Disease Centre, which she co-founded with Professor Gill Bates in 2016. She is also joint Head of Department for Neurodegenerative Diseases at the UCL Queen Square Institute of Neurology, a principal investigator at the UK Dementia Research Institute, and Honorary Consultant Neurologist at the National Hospital for Neurology and Neurosurgery. In addition to a basic bench science programme focussing on basic cellular mechanisms of neurodegeneration in Huntington’s disease (HD), Tabrizi also leads a large translational research programme that aims to find effective disease-modifying treatments for HD. Tabrizi was global clinical principal investigator on the world’s first gene silencing study for HD using antisense oligonucleotide therapy. The results from this trial showed the first antisense mediated knockdown of a toxic protein in the CNS of adults. Tabrizi was elected as a fellow of the UK Academy of Medical Sciences in 2014. In 2017, she received the seventh Leslie Gehry Brenner Prize for Innovation in Science awarded by the Hereditary Disease Foundation. In 2018, she received the Cotzias Award from the Spanish Society of Neurology, and, in 2019, the Yahr Award at the World Congress for Neurology and the Alexander Morison Medal from the Royal College of Physicians of Edinburgh.
« Go Back